Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick [Yahoo! Finance]
Tenax Therapeutics, Inc. (TENX)
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.tenaxthera.com
Company Research
Source: Yahoo! Finance
on Tenax Therapeutics Inc (NASDAQ:TENX) to $25 from $14 and maintained a Buy rating. The firm stated that its decision to nearly double the price target for Tenax relies on a specific divergence in the market. That is, while competitors target small patient subgroups, Tenax is pursuing a massive, untreated population with no current competition in late-stage trials. Source: Pexels Guggenheim noted that Tenax has successfully cleared its financial hurdles and that it has secured enough capital to fund operations through major clinical milestones in 2026. And for that reason, the firm reiterated Tenax as a “Top Pick for 2026.” This designation, Guggenheim stated, focuses on the anticipation of the first pivotal readout from the LEVEL trial for the oral levosimendan (TNX-103) drug, which is expected in the second half of 2026. Meanwhile, on December 17, Tenax conducted a pre-planned statistical review of the first 150 patients in its LEVEL study. And, the company said that the revi
Show less
Read more
Impact Snapshot
Event Time:
TENX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TENX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TENX alerts
High impacting Tenax Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TENX
News
- Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing [Seeking Alpha]Seeking Alpha
- Tenax Therapeutics (NASDAQ:TENX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size AssessmentGlobeNewswire
- Tenax Therapeutics (NASDAQ:TENX) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Tenax Therapeutics (NASDAQ:TENX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
TENX
Sec Filings
- 1/9/26 - Form 8-K
- 12/23/25 - Form SCHEDULE
- 12/17/25 - Form 8-K
- TENX's page on the SEC website